- Market Capitalization, $K 34,600
- Shares Outstanding, K 26,822
- Annual Sales, $ 0 K
- Annual Income, $ -80,530 K
- 60-Month Beta 2.39
- Price/Sales N/A
- Price/Cash Flow N/A
- Price/Book N/A
|Period||Period Low||Period High||Performance|
| || |
-0.1900 (-12.84%)since 06/01/22
| || |
-1.0500 (-44.87%)since 04/01/22
| || |
-8.8000 (-87.22%)since 07/01/21
Rucosopasem was safe and well tolerated Early indications of anti-cancer activity and pulmonary function preservation Enrollment ongoing in the...
MALVERN, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on...
Avasopasem produced clinically meaningful, statistically significant reduction of severe oral mucositis (SOM) in patients with locally advanced head and...
Company plans to submit a New Drug Application (NDA) for avasopasem for the treatment of radiotherapy-induced severe oral mucositis (SOM) by end of 2022 ...
After discussions with FDA, Company is on track to file an NDA for avasopasem for the treatment of radiotherapy-induced severe oral mucositis by end of...
MALVERN, Pa., April 27, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on...
Editas (EDIT) doses the first patient pediatric patient in the BRILLIANCE study on EDIT-101 for treating Leber congenital amaurosis 10 (LCA10).
Aptinyx's (APTX) phase IIb study evaluating the effects of NYX-2925 in patients with painful diabetic peripheral neuropathy misses the primary endpoint. Stock falls sharply.
The European Commission grants marketing authorization to Bristol Myers' (BMY) Breyanzi for treating certain forms of relapsed or refractory large b-cell lymphoma.
Positive Phase 3 ROMAN trial of avasopasem for severe oral mucositis met primary and secondary endpoint; Company intends to meet with FDA in 2022 about NDA...
|3rd Resistance Point||1.4367|
|2nd Resistance Point||1.3633|
|1st Resistance Point||1.3267|
|1st Support Level||1.2167|
|2nd Support Level||1.1433|
|3rd Support Level||1.1067|